BDPAZO contains pazopanib, a targeted therapy used primarily in the treatment of certain advanced cancers, including kidney cancer and soft tissue sarcoma. It belongs to a class of medications known as tyrosine kinase inhibitors and is taken orally. Pazopanib works by interfering with the growth of cancer cells and their blood supply. It is often used in patients whose disease has spread or who are not candidates for surgery or other forms of curative treatment.

Mechanism of Action
Pazopanib blocks the activity of several enzymes known as tyrosine kinases that are involved in the growth of blood vessels that supply tumors. Specifically, it inhibits vascular endothelial growth factor receptors, platelet-derived growth factor receptors, and other related receptors. These enzymes play a critical role in the process of angiogenesis, where new blood vessels form to feed cancer cells. By shutting down these pathways, BDPAZO reduces the blood supply to tumors, effectively starving them and slowing their growth or spread.

Uses
BDPAZO is primarily used to treat:

• Advanced renal cell carcinoma, a type of kidney cancer

• Advanced soft tissue sarcoma, particularly in patients who have received prior chemotherapy
  In some cases, pazopanib may be explored for use in other solid tumors, under the guidance of a specialist. It is not a cure but can help control the disease and improve quality of life or survival.

• Adverse Effects
  Like many cancer therapies, BDPAZO may cause side effects, though not everyone will experience them. Common side effects include tiredness, diarrhea, high blood pressure, changes in hair color, nausea, and loss of appetite. Liver function changes are relatively common and need close monitoring through blood tests. Serious but less frequent side effects can include heart rhythm disturbances, bleeding, and clotting issues. Some people may develop reversible damage to the heart or liver if not monitored carefully. Regular follow-ups and dose adjustments can help manage these risks.